Figure 4.

Combination of EGCG and CTGF siRNA for inhibition of resistant breast cancer. (A) Schematic illustration of the combination therapy for inhibiting CTGF-overexpressed breast cancer. (B) The enhanced cytotoxicity by the combined treatment in MDA-MB-231 cells. (C) Downregulation of drug resistance-associated proteins in MDA-MB-231 cells by the combination therapy. (D) The reduced tumor volume on xenografted mice by the combined treatment. Reproduced from ¹³¹ with permission from American Chemical Society.